The U.S. Food and Drug Administration on November 16 authorized a virtual reality system from Applied VR for reducing lower back pain after a majority of patients in a trial testing the device showed lesser discomfort.
Kate Cronin, Global CEO of Ogilvy Health, shares her views on a variety of healthcare industry topics in a Q&A with PharmaLive.
COVID-19 has dramatically altered many of the traditional means of communication and education in the medical community. As often happens in a major crisis, innovations have evolved at lightning speed. Healthcare audience outlooks and expectations have also taken permanent turns.
Outcome Health announced the OH Virtual Waiting Room, ushering the Point of Care sector into telemedicine with an empathetic, unique patient experience whenever and wherever patients are meeting with their physicians.
Businesses, professional bodies and individual practitioners have to keep talking at a time like this, not least because patients’ non-Covid-related needs have not disappeared overnight. How are lines of communication holding up, and what might this tell us about life after Covid-19?
The importance of patient satisfaction is no more important today than it was yesterday. The difference is we now have the technology and tools available to bring it to life. We are continually learning about the needs of healthcare providers and patients, and will not stop seeking new and innovative way to share those insights in order to improve patient care.
Immersion in virtual reality may relieve some of the pain of contractions before childbirth, a small study suggests.
With a technology like VR, arguably even more so than in live settings, we can readily tap into multiple learning styles by integrating different types of media into a single experience.
I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.
Eight medical device makers – including a startup that uses virtual reality to treat chronic pain – topped an innovation contest aimed at addressing the opioid crisis, the U.S. FDA said.